BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17302608)

  • 1. E-cadherin and beta-catenin expression patterns in malignant melanoma assessed by image analysis.
    Pećina-Slaus N; Zigmund M; Kusec V; Martić TN; Cacić M; Slaus M
    J Cutan Pathol; 2007 Mar; 34(3):239-46. PubMed ID: 17302608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E-cadherin/catenin complex in benign and malignant melanocytic lesions.
    Silye R; Karayiannakis AJ; Syrigos KN; Poole S; van Noorden S; Batchelor W; Regele H; Sega W; Boesmueller H; Krausz T; Pignatelli M
    J Pathol; 1998 Dec; 186(4):350-5. PubMed ID: 10209482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of beta-catenin, E-cadherin, cyclin D1 and c-myc in benign trichogenic tumors.
    Demirkan NC; Bir F; Erdem O; Düzcan E
    J Cutan Pathol; 2007 Jun; 34(6):467-73. PubMed ID: 17518774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
    Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
    J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas.
    Kim MJ; Jang SJ; Yu E
    Hum Pathol; 2008 Feb; 39(2):251-8. PubMed ID: 17959228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
    Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
    Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors.
    Chetty R; Serra S; Asa SL
    Am J Surg Pathol; 2008 Mar; 32(3):413-9. PubMed ID: 18300809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma.
    Tucci MG; Lucarini G; Brancorsini D; Zizzi A; Pugnaloni A; Giacchetti A; Ricotti G; Biagini G
    Br J Dermatol; 2007 Dec; 157(6):1212-6. PubMed ID: 17970806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent occurrence of abnormal E-cadherin/beta-catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis.
    Hirata K; Ajiki T; Okazaki T; Horiuchi H; Fujita T; Kuroda Y
    Oncology; 2006; 71(1-2):102-10. PubMed ID: 17341890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract.
    Kashibuchi K; Tomita K; Schalken JA; Kume H; Yamaguchi T; Muto S; Horie S; Kitamura T
    Eur Urol; 2006 May; 49(5):839-45; discussion 845. PubMed ID: 16426728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis.
    Chen S; Liu J; Li G; Mo F; Xu X; Zhang T; Zhang X; Li J; Han X; Sun Y
    Scand J Gastroenterol; 2008; 43(4):456-64. PubMed ID: 18365911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.
    Maelandsmo GM; Holm R; Nesland JM; Fodstad Ø; Flørenes VA
    Clin Cancer Res; 2003 Aug; 9(9):3383-8. PubMed ID: 12960126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cadherin/catenin cell--cell adhesion molecules in a onychomatricoma.
    Burchette JL; Pham TT; Higgins SP; Cook JL; Soler AP
    Int J Surg Pathol; 2008 Jul; 16(3):349-53. PubMed ID: 18573792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer.
    Boo YJ; Park JM; Kim J; Chae YS; Min BW; Um JW; Moon HY
    Ann Surg Oncol; 2007 May; 14(5):1703-11. PubMed ID: 17211730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-cadherin suppression accelerates squamous cell carcinoma progression in three-dimensional, human tissue constructs.
    Margulis A; Zhang W; Alt-Holland A; Crawford HC; Fusenig NE; Garlick JA
    Cancer Res; 2005 Mar; 65(5):1783-91. PubMed ID: 15753375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-cadherin and beta-catenin mRNA levels throughout colon cancer progression.
    Truant SC; Gouyer VP; Leteurtre EA; Zerimech F; Huet GM; Pruvot FR
    J Surg Res; 2008 Dec; 150(2):212-8. PubMed ID: 18316097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cadherin/catenin complex in malignant melanoma.
    Bonitsis N; Batistatou A; Karantima S; Charalabopoulos K
    Exp Oncol; 2006 Sep; 28(3):187-93. PubMed ID: 17080010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis.
    Itatsu K; Zen Y; Ohira S; Ishikawa A; Sato Y; Harada K; Ikeda H; Sasaki M; Nimura Y; Nakanuma Y
    Liver Int; 2007 Nov; 27(9):1174-84. PubMed ID: 17919228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell adhesion protein expression in melanocytic matricoma.
    Soler AP; Burchette JL; Bellet JS; Olson JA
    J Cutan Pathol; 2007 Jun; 34(6):456-60. PubMed ID: 17518772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoexpression of beta-catenin--E-cadherin complex in primary serous ovarian tumors.
    Stawerski P; Wagrowska-Danilewicz M; Stasikowska O; Gottwald L; Danilewicz M
    Pol J Pathol; 2008; 59(1):27-32. PubMed ID: 18655368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.